Objective: To find the factors related as predictive factors for Gleason score in prostate cancer patients. Material & methods: This study obtained a total sample of 144 patients with prostate cancer in Sardjito General Hospital Yogyakarta in 2009-2013. Of the total 144 patients, only 64 patients had complete medical records. All patient samples were patients who had biopsy of the prostate. This study is a retrospective case-control study to predict the Gleason Score in patients with prostate cancer in terms of age, total prostate specific antigen (PSA), PSA density and TAUS. Normality test assessed the distribution of the data. Pearson test assessed normal distribution and Spearman test for normal distribution. All data were analyzed using SPSS version 18. Results: Analysis of data from 64 patients with prostate cancer with a normal distribution of the variables obtained on age and TAUS with p > 0.05 whereas abnormal distribution obtained on total PSA, PSA density with p < 0.05. Of the data on the data with a normal distribution, age and TAUS with values obtained p 0.039 and p 0.738. From these data it can be said there is a relationship between age and Gleason score where the higher the age the higher the Gleason score. TAUS of the data can be said there is no relationship between TAUS and Gleason score. Then the abnormal distribution of the data obtained with a total PSA p < 0.001 and PSA density p < 0.001. The data is obtained from the relationship between total PSA and PSA density with Gleason score. Conclusion: It was found that age, total PSA, PSA density affect the increase in Gleason score where the higher the age, total PSA and PSA density the higher the Gleason score in patients.
Prostate cancer, total prostate specific antigen, prostate specific antigen density, TAUS, Gleason score
Stacy L, Herbert B. Early detection, diagnosis, and staging of prostate cancer, in Campbell-Walsh Urology. 10th ed. Saunders: Philadelphia USA; 2012. p. 2764.
Bittner N, Gregory S, Andreini H, Taunbenslag W, Allen ZA, Butler WM, et al. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. J Urol; 2009.
Giannarini G, Scott C, Moro U, Pertoldi B, Beltrami CA, Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer. Urology Oncology: Seminars and Investigation; 2008. p. 353-60.
Stav K, Judith S, Merald H, Leibovici H, Lindner A, Zisman A. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer. Urology Oncology; 2007. p. 382-86.
Andre N, Roemeling S, Kranse Ries, Scholder FH, Van Der Kwast TH. Should we replace the Gleason score with the amount of high-grade prostate cancer. European Association of Urology; 2007. p. 931-39.
Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urology Oncology: Seminars and Investigation; 2007. p. 376-82.
Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (¸12)-core prostate biopsy. J Urol; 2009. p. 271-76.
Munterner M, Epstein J, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, et al. Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. European Association of Urology; 2008. p. 767-76.
Alenda O, Ploussard G, Mouracade P, Xylinas E, Taille AD, Allory Yves, et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. J Urol; 2011. p. 671-76.
Rapiti E, Schaffar R, Iselin C, Mirabell R, Pelte MF, Weber D, et al. Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. BMC Urology; 2011. p. 13-19.
Krane LS, Menon M, Kaul SA, Siddiqui SA, Wambi C, Peabody JO, et al. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urology Oncology: Seminars and Investigation; 2011. p. 372-77.